Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Therapeutics|July 1, 1996
The total process cost of parenteral antibiotic therapy: beyond drug acquisition costL Hotchkies, D T Grima, S Hedayati
European Journal of Ophthalmology|September 2, 2003
Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in FranceL M Bernard, R Althin, R Dhawan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 17, 2007
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysisD T Grima, A Papaioannou, M F Thompson, et al.
Current Oncology (Toronto, Ont.)|February 25, 2010
Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in CanadaC L Attard, J A Maroun, K Alloul, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2000
Cost and health related quality of life consequences of multiple sclerosisD T Grima, G W Torrance, G Francis, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 22, 2001
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventionsA N Tosteson, B Jönsson, D T Grima, et al.
Bone Marrow Transplantation|June 11, 2013
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF aloneA D Sung, D T Grima, L M Bernard, et al.
Pageof 1